Company Overview

Vaxart, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of oral recombinant protein vaccines delivered in tablet form. The company operates within the biotechnology, immunology, and vaccine development industries, with an emphasis on replacing or supplementing traditional injectable vaccines through room-temperature-stable oral immunization technologies. Its primary research and development programs have targeted infectious diseases including COVID-19, norovirus, influenza, and other viral pathogens.

The company’s core strategic differentiator is its proprietary oral vaccine platform, which is designed to stimulate both systemic and mucosal immune responses while potentially improving distribution logistics and patient compliance compared with injectable vaccines. Vaxart traces its origins to vaccine platform development work that predated its merger with Aviragen Therapeutics, Inc. in 2018, after which the combined company adopted the Vaxart name and continued advancing oral vaccine candidates through clinical development. Public filings and investor materials consistently identify clinical-stage vaccine development and platform licensing as the company’s principal business activities.

Business Operations

Vaxart primarily operates as a clinical-stage biotechnology company and does not currently generate material recurring commercial product revenue based on publicly available filings. Its operations are centered on the development of oral tablet vaccine candidates using its proprietary vector and delivery technologies. The company’s programs have included candidates for COVID-19, seasonal influenza, norovirus, and avian influenza strains, with revenue historically derived from collaboration agreements, government contracts, grants, and financing activities rather than approved product sales.

The company conducts most of its operations in the United States, including research, clinical development, regulatory engagement, and corporate administration. Vaxart has collaborated with external manufacturing organizations, academic institutions, and government agencies to support clinical studies and production activities. Public disclosures also reference relationships with organizations involved in biodefense and pandemic preparedness initiatives, including participation in programs associated with U.S. government funding opportunities. Its core assets include its oral vaccine delivery platform, proprietary adenoviral vector technologies, and related intellectual property portfolio supporting mucosal immunization approaches.

Strategic Position & Investments

Vaxart’s strategic direction has focused on advancing oral vaccine technologies that could simplify vaccine administration and storage while improving scalability during infectious disease outbreaks. The company has prioritized clinical development programs aimed at respiratory and gastrointestinal viruses, particularly where mucosal immunity may offer competitive advantages. Management communications and regulatory filings indicate continued investment in platform validation through human clinical trials and immunogenicity studies.

The company has also pursued partnerships and funding arrangements intended to support development costs and expand manufacturing readiness. Vaxart’s COVID-19 oral vaccine program significantly increased the company’s visibility during the pandemic period, while later-stage strategic emphasis expanded toward broader pandemic preparedness and oral immunization applications. Public information identifies ongoing investment in tablet-based vaccine delivery technologies, next-generation vector optimization, and programs aligned with emerging infectious disease response initiatives. Data regarding long-term commercialization partnerships and future market adoption remains dependent on clinical and regulatory outcomes.

Geographic Footprint

Vaxart is headquartered in South San Francisco, California, and its operational footprint is concentrated primarily within the United States. The company’s clinical development activities, corporate functions, and strategic partnerships are largely U.S.-based, although clinical trial activities and manufacturing support have involved international vendors and research collaborators.

The company’s market focus is global in scope because infectious disease vaccine development inherently targets international public health demand. Vaxart has discussed opportunities related to global vaccine accessibility, particularly in regions where cold-chain logistics create barriers for injectable vaccines. While the company does not currently maintain the broad commercial infrastructure of multinational pharmaceutical firms, its technology platform is intended for potential deployment across multiple geographic markets subject to regulatory approvals and partnership arrangements.

Leadership & Governance

Vaxart is governed by a board of directors and executive leadership team with backgrounds in biotechnology, pharmaceuticals, immunology, finance, and public company management. Corporate governance practices are outlined in the company’s public filings, including annual reports and proxy statements. Leadership strategy has consistently emphasized advancing oral vaccine innovation, securing development funding, and progressing clinical candidates through regulatory pathways.

Key executives and leadership figures have included:

• Steven Lo – Chief Executive Officer and Chair of the Board
• Andrew Floroiu – President
• Sean Tucker – Senior Vice President and Founder
• Phillip B. Norman – Chief Financial Officer
• James F. Cummings – Chief Medical Officer

Management communications have emphasized the company’s objective of establishing oral vaccination as a scalable alternative within infectious disease prevention, with strategic focus on clinical validation, manufacturing readiness, and platform expansion.